Pembrolizumab Plus Chemo With or Without Bevacizumab Maintai

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

Pembrolizumab plus chemotherapy with or without bevacizumab led to a substantial improvement in overall survival vs placebo plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the KEYNOTE-826 trial.

Related Keywords

Colombo , Western , Sri Lanka , , Pembrolizumab Plus Chemotherapy With Or Without Bevacizumab , Patients With Persistent , Recurrent , R Metastatic Cervical Cancer , Final Os Analysis Of The Keynote 826 Trial , 2023 Asco Annual Meeting ,

© 2025 Vimarsana